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Abstract
Introduction: To evaluate the efficacy of probiotics in preventing nosocomial pneumonia in critically ill patients.
Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted
data and reviewed the quality of the studies independently. The primary outcome was the incidence of
nosocomial pneumonia. Study-level data were pooled using a random-effects model when I2 was > 50% or a
fixed-effects model when I2 was < 50%.
Results: Twelve randomized controlled studies with a total of 1,546 patients were considered. Pooled analysis
showed a statistically significant reduction in nosocomial pneumonia rates due to probiotics (odd ratio [OR]= 0.75,
95% CI 0.57 to 0.97, P = 0.03, I2 = 46%). However, no statistically significant difference was found between groups
regarding in-hospital mortality (OR = 0.93, 95% CI 0.50 to 1.74, P = 0.82, I2 = 51%), intensive care unit mortality (OR =
0.84, 95% CI 0.55 to 1.29, P = 0.43, I2 = 0%), duration of stay in the hospital (mean difference [MD] in days = -0.13,
95% CI -0.93 to 0.67, P = 0.75, I2 = 46%), or duration of stay in the intensive care units (MD = -0.72, 95% CI -1.73 to
0.29, P = 0.16, I2 = 68%).
Conclusions: The use of probiotics was associated with a statistically significant reduction in the incidence of
nosocomial pneumonia in critically ill patients. However, large, well-designed, randomized, multi-center trials are
needed to confirm any effects of probiotics clinical endpoints such as mortality and length of ICU and hospital
stay.
Introduction
Nosocomial pneumonia (NP) is a common complication
in critically ill patients, particularly in patients who are
intubated for more than 48 hours, and NP is responsible
for significant in-hospital morbidity and mortality [1-3].
When mechanically ventilated patients develop NP, it is
known as ventilator-associated pneumonia (VAP) [1,2].
Multiple hospital-associated risk factors for NP have
been identified. These risk factors are thought to contri-
bute to increased bacterial colonization of the aerodiges-
tive tract and facilitate the entry of pathogenic bacteria
into the lower respiratory tract [4].
Considerable efforts have been made to evaluate
methods for reducing NP. For example, selective diges-
tive tract decontamination in critically ill patients has
been shown to reduce the occurrence of NP; however
such decontamination has also been associated with
increased rates of antimicrobial resistance [5,6]. Several
experimental and clinical studies have suggested a pro-
mising effect of probiotics on preventing NP in critically
ill patients [7-10].
Probiotics are commercially available microorganisms
that when ingested as individual strains or in combination
may offer potential health benefits to the host [11]. Prebio-
tics are non-digestible sugars that selectively stimulate the
growth of certain bacteria colonies. The combination of
pre- and probiotics has been designated as synbiotics. It is
hypothesized that probiotics could potentially reduce the
incidence of NP in critically ill patients through various
local and systemic effects that minimize colonization by
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more virulent species or optimize host immune defenses.
These effects include reducing overgrowth of potentially
pathogenic microorganisms, enhancing gut barrier func-
tion, reducing bacterial translocation, and up-regulation of
immune functions [12-19].
To date, clinical research concerning the effects of pro-
biotics in critically ill patients have provided conflicting
results, with some suggesting clinical benefit [20-29], and
others showing no benefit [30-33]. More recently, one
study showed that probiotics therapy led to a significant
reduction in VAP rates among treated patients [22]. How-
ever, another study showed that daily prophylactic admin-
istration of probiotics was not effective for critically ill
patients, notably for those with non-severe sepsis [30].
Therefore, we performed a systematic literature review
and meta-analysis to investigate the effects of probiotics
in critically ill patients using incidence of NP as the pri-
mary outcome, and mortality, length of stay in the ICU
and in hospital, and adverse outcomes as secondary
outcomes.
Materials and methods
Data sources and search strategy
To identify studies for inclusion in this review, two
authors independently searched PubMed, the Cochrane
Central Database of Controlled Trials, and EMBASE for
relevant studies published up to January 2012. The search
was limited to studies conducted in humans. No language
restriction was imposed. Search terms were individua-
lized for each database. Search terms used included:
[’pneumonia’ OR ‘critically ill’ OR ‘intensive care’ OR
‘trauma’ OR ‘pancreatitis’ OR ‘surgical patients’] AND
[’probiotics’ OR ‘prebiotics’ OR ‘synbiotics’ OR ‘lactoba-
cillus’ OR ‘bifidobacterium’]. We also searched the pro-
ceedings of major relevant conferences, trial databases,
the reference lists of identified trials, and major reviews.
Study selection
Two reviewers (KXL and YGZ) independently screened
studies for inclusion, retrieved potentially relevant stu-
dies, and determined study eligibility. Any discrepancies
were resolved by consensus. Analysis was restricted to
double-blind, randomized controlled trials (RCTs). For
this meta-analysis, we considered those RCTs that com-
pared administration of probiotics vs. placebo in criti-
cally ill patients (such as those admitted to an ICU or
having recently undergone abdominal or another major
surgical procedure), and that reported the incidence of
NP or VAP. Probiotics could be administered either
alone or in combination with prebiotics.
Data extraction
Two authors independently extracted data from all of
the enrolled studies. Extracted data included study
design (for example, year conducted, sample size),
patient characteristics, study methodology (for example,
eligibility criteria, method of randomization and blind-
ing), intervention (for example, type of probiotic agent,
dose, route of its administration and duration), and clin-
ical outcomes. The primary outcome was the incidence
of NP. We used the authors’ definitions for NP if they
included clinical and radiological criteria. Secondary
outcomes were mortality, length of stay in ICU and in
hospital, and reports of adverse outcomes.
Quality assessment
We formally assessed the methodological quality of each
trial using the Jadad score [34], which incorporates ran-
domization, blinding, and attrition to derive a score of 0
to 5; higher scores indicate higher quality. Two
reviewers (KXL and YGZ) independently appraised the
quality of the included trials. Studies were considered to
be of low quality if the Jadad score was ≤ 2 and high
quality if the score was ≥ 3.
Statistical analysis
The meta-analysis was performed using Review Manager
5.0 (Cochrane Collaboration, Oxford, UK). We com-
puted pooled odds ratios (ORs) and 95% confidence
intervals (CIs) from the adjusted ORs and 95% CIs
reported in the observational studies. We used Cochrane
Q and I2 statistics to assess the heterogeneity of study
results. We predefined heterogeneity as low, moderate
or high with I2 values above 25%, 50%, and 75%, respec-
tively. In the analysis of heterogeneity, we considered a
P-value < 0.10 statistically significant. Study-level data
were pooled using a random-effects model when I2 was
> 50% or a fixed-effects model when I2 was < 50%. Pub-
lication bias was assessed by a funnel plot using the
occurrence of NP as an endpoint.
Results
Our search retrieved a total of 131 references. After
applying the inclusion criteria, twelve studies were
included in this meta-analysis [22-33]. A flowchart for
the studies evaluated and the reasons for exclusion are
shown in Figure 1.
Study characteristics
Characteristics of the included studies are summarized
in Table 1. A total of 1,546 critically ill patients were
included in these studies. All studies were published
from 2002 to 2011. Trials were conducted in a diverse
array of countries. Most of the trials were carried out at
a single center. Four studies recruited patients in general
ICUs [22,30-32], eight studies recruited patients in sur-
gical ICUs [23-29,33], one study recruited patients who
were scheduled for liver transplantation [26], and one
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study recruited patients with severe acute pancreatitis
[33]. Seven of the twelve clinical trials enrolled patients
who required mechanical ventilation (MV) from medical
and surgical ICUs [22,23,28-32]. The frequency of
probiotic administration ranged from once to twice a
day. In the majority of eligible trials, probiotics were
administered via nasogastric or orogastric tube
[22,23,28-32] until the patient’s discharge from the ICU
Potential relevant published articles 
identified: (n=131)
84 excluded for the following reasons: review 
articles/meta-analysis/comments and editorials/ Letter to 
editor/ case reports/
Articles retrieved for more detailed 
evaluation:᧤n=47᧥
25 excluded for the following reasons:
Not a randomized controlled study᧤n=3᧥
Evaluating in animal experiments᧤n=13᧥
Pediatric study᧤n=9᧥
Articles meeting inclusion criteria for this 
meta-analysis: ᧤n=22᧥
10 excluded for the following reason:
Not relevant to the main outcome᧤n=5᧥
Population not critically ill᧤n=3᧥
Inappropriate control group᧤n=2᧥
Articles included in this meta-
analysis: 12
Figure 1 Flow chart of study selection. Pooled ORs were calculated using the Mantel-Haenszel (M-H)Estimator. Study-level data were pooled
using a random-effects model when I2 was > 50% or a fixed-effects model when I2 was < 50%.
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or death. In some surgical patients, probiotics were
administered via nasojejunal tubes [24-27,33]. The aver-
age Jadad score of these studies was 3.5 (range 2.0 to
5.0) (Table 2). Results of the meta-analyses that explored
the effects of probiotics on clinical outcomes are shown
in Table 3.
Nosocomial pneumonia and subgroup analyses
Results from twelve trials (1,546 patients) were available
to examine the effects of oral probiotics on the inci-
dence of NP. A low level of heterogeneity was found
among the identified comparisons (I2 = 46%, P = 0.04).
Pooled analysis showed that the use of probiotics was
associated with a statistically significant reduction in the
incidence of NP in critically ill patients (OR = 0.75, 95%
CI 0.57 to 0.97, P = 0.03) (Figure 2).
We also performed subgroup analyses after stratifying
trials by critically ill patients requiring MV (see Addi-
tional File 1) and surgical critically ill patients (see Addi-
tional File 2). Seven studies reported the incidence of
VAP [22,23,28-32]. No statistically significant difference
in the incidence of VAP was found between patients
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who received probiotics and patient controls (OR = 0.68,
95% CI 0.42 to 1.11, P = 0.12, I2 = 54%). We noted a
marginally significant beneficial effect of probiotics on
reducing the rate of NP in critically ill surgical patients
in a meta-analysis that included eight studies (OR =
0.67, 95% CI 0.45 to 1.01, P = 0.05, I2 = 41%) [23-29,33].
Overall mortality
Results of nine trials were available for the analysis of
mortality during the entire hospital stay
[22-27,29,32,33]. A meta-analysis of these trials found
that probiotics administration had no effect on overall
mortality during the hospital stay (OR = 0.93, 95% CI
Table 2 Quality of the twelve studies as assessed by the Jadad score [34]
Study Randomization Blinding Withdrawals and dropouts Quality Score
Barraud et al. [30] 2 2 1 5
Besselink et al. [33] 2 2 1 5
Forestier et al. [31] 2 2 1 5
Giamarellos-Bourboulis et al. [23] 1 2 0 3
Kanazawa et al. [24] 1 1 0 2
Knight et al. [32] 2 2 1 5
Morrow et al. [22] 1 2 1 4
Rayes et al. [25] 2 0 1 3
Rayes et al. [26] 2 1 1 4
Spindler-Vesel et al. [28] 1 1 0 2
Tan et al.[29] 2 1 1 4
Each article was scored using a five-point scale that evaluates randomisation, blinding and completeness of patient follow-up (Jadad scale). One point was given
if the study was described as randomised. An additional point was given if the randomisation method was described and was appropriate (for example,
computer-generated table of random numbers), whereas a point was subtracted if the randomisation method was described and inappropriate. Similarly, one
point was assigned to studies described as double-blinded, two points were assigned to studies for which the double-blinding method was described and
appropriate (for example, identical placebo, active placebo,double-dummy) and zero points were assigned to studies for which the double-blinding method was
described and inappropriate. One point was given if the article specified the numbers of and reasons for withdrawals and dropouts.
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0.50 to 1.74, P = 0.82) (Figure 3). We did find evidence
of statistical heterogeneity for in-hospital mortality (I2
= 51%, P = 0.07). Only three of the twelve selected
RCTs provided information regarding mortality during
an ICU stay [28,30,32]. There was no significant differ-
ence in ICU mortality between a probiotics group and
a placebo group (OR = 0.84, 95% CI 0.55 to 1.29, P =
0.43) (Figure 4). There was no heterogeneity between
trials (I2 = 0%).
Duration of stay in the hospital
Eight studies were included in the analysis of the length
of stay in hospital [22,24-27,30,32,33]. There was no
apparent effect of probiotics therapy on the duration of
stay in hospital, with a mean difference (MD) of -0.13
days (95% CI -0.93 to 0.67, P = 0.75) (Figure 5). A low
level of heterogeneity was found among these compari-
sons (I2 = 46%, P = 0.07).
Duration of stay in the intensive care unit
Data from eight studies were included in the analysis of
the duration of stay in the intensive care unit
[22,24,26,27,29,30,32,33]. There was significant hetero-
geneity in length of ICU stays (I2 = 68%, P = 0.002)
(Figure 6). There was no significant difference between
the compared groups regarding this outcome (MD in
days = -0.72, 95% CI -1.73 to 0.29, P = 0.16).
Adverse events
The following adverse events were reported: diarrhea,
abdominal cramps and bowel ischemia [22,25-27,32,33].
Data regarding the incidence of diarrhea were provided in
six of the twelve included RCTs [22,25-27,32,33]. There
was no difference between probiotics and placebo groups
in the incidence of diarrhea (OR= 0.85, 95% CI 0.58 to
1.26, P = 0.43, I2 = 0%). There was no significant difference
between probiotics and placebo groups in the incidence of
abdominal cramps in the meta-analysis that included only
three RCTs (OR = 0.74, 95% CI 0.47 to 1.17, P = 0.19, I2 =
0%) [25,26,33].
Publication bias
Upon visual inspection of the funnel plot for the pri-
mary outcome, we found evidence of publication bias
Figure 2 Forest plot showing the effect of probiotics on the occurrence of nosocomial pneumonia (NP) in critical ill patients. Pooled
ORs were calculated using the Mantel-Haenszel (M-H)Estimator. Study-level data were pooled using a random-effects model when I2 was > 50%
or a fixed-effects model when I2 was < 50%.
Figure 3 Forest plot showing the effect of probiotics on in-hospital mortality. Pooled ORs were calculated using the Mantel-Haenszel (M-
H)Estimator. Study-level data were pooled using a random-effects model when I2 was > 50% or a fixed-effects model when I2 was < 50%.
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(absence of small studies, shown in the right lower cor-
ner of Figure 7).
Discussion
Our meta-analysis found that probiotics administration
was associated with statistically significant reduction in
the incidence of NP in critically ill patients. However,
the pooled results showed that probiotics did not affect
overall mortality, or length of stay in the hospital and
the ICU, which were the secondary endpoints of the
study.
The current meta-analysis is different from previous
reviews in several aspects. Although three recent reviews
addressed somewhat similar questions, our meta-analysis
identified and included more eligible studies than the pre-
vious reviews [35-37]. These previous reviews on probio-
tics administration included studies that recruited patients
requiring MV only [35] or studies of surgical patients only
[36]. Thus, those meta-analyses were limited to selected
populations. Trials of any type of critically ill patients were
eligible for our study, and therefore our results are applic-
able across a wide range of clinical situations that are
encountered with critically ill patients. In order to
diminish the number of confounding factors, we excluded
two studies using chlorhexidine and antibiotic decontami-
nation as control groups, because the use of chlorhexidine
in oral care procedures and antibiotic decontamination of
the digestive tract were considered to be effective in pre-
venting NP [6,21]. The review by Siempos et al. used the
data from one trial on the rate of respiratory tract infec-
tion as the rate of VAP [35], which may have contributed
to an overestimation of the VAP rate and a greater
observed treatment effect. This trial has been recently
published in a separate study [23] and confirms that there
are fewer patients with VAP than with respiratory tract
infections. Accordingly, we included the latter study in our
meta-analysis. Our results appear similar to the previous
reviews by Siempos et al. [35] and Pitsouni et al. [36], but
inconsistent with the results of the systematic review by
Watkinson et al. [37]. Siempos et al. found that adminis-
tration of probiotics was beneficial in the incidence of
both VAP and NP, length of stay in the ICU and coloniza-
tion rates of Pseudomonas aeruginosa in the respiratory
tract [35]. Similarly, the meta-analysis by Pitsouni et al.
demonstrated that probiotics significantly reduced the
occurrence of postoperative pneumonia and any infectious
Figure 4 Forest plot showing the effect of probiotics on ICU mortality. Pooled ORs were calculated using the Mantel-Haenszel (M-H)
Estimator. Study-level data were pooled using a random-effects model when I2 was > 50% or a fixed-effects model when I2 was < 50%.
Figure 5 Forest plot showing the effect of probiotics on length of hospital stay (in days). Mean differences were estimated by the inverse
variance (IV) approach.
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complications, as well as the duration of postoperative
hospital stay [36]. While we restricted our subgroup analy-
sis to patients in surgical populations, a pooled analysis
showed a marginally non-significant reduction in NP in
favor of probiotics. In contrast, Watkinson et al. pooled
eight trials and found that pre- pro- or synbiotics were not
associated with any significant change in the outcomes
studied, that is, length of ICU stay, hospital mortality and
the incidence of nosocomial infection and more specifi-
cally incidence of pneumonia [37]. Although there was no
statistically significant effect on the incidence of NP in all
subgroups, the risk reduction associated with probiotics
use was substantial. The reasons for these inconsistent
results may partly be due to differences in focus on clinical
outcomes.
The results of this meta-analysis should be interpreted
carefully based on other considerations. As the diagnosis
of pneumonia is a more subjective outcome than mortality
or length of stay in the ICU, it may be more subject to
bias, and this may in part explain the marked reduction in
pneumonia found in these studies. In addition, the defini-
tions of pneumonia varied among different studies, which
will affect the true nature of clinical outcomes. In addition,
the absence of an effect on secondary outcomes may be
from the small number of pooled RCTs and total patients.
And lastly, the treatment durations in some studies were
likely too short to demonstrate maximal benefits. Conse-
quently, a lack of standard protocols and insufficient num-
bers of patients may make it difficult to derive conclusive
results based on the current meta-analysis.
Figure 6 Forest plot showing the effect of probiotics on length of ICU stay (in days). Mean differences were estimated by the inverse
variance (IV) approach.
Figure 7 Funnel plot showing possibility of a small publication bias. SE, standard error: OR, odds ratio.
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The potential harm due to probiotics therapy also
warrants comment. The numbers of patients with diar-
rhea or abdominal cramps did not differ between those
patients who received probiotics and those who did not
in our current meta-analysis. However, a particular con-
cern in critically ill patients is whether their exposure to
probiotics places them at risk for developing an invasive
infection. There were no reports of bacteremia or sepsis
due to probiotics in the studies included in our meta-
analysis. In addition, Besselink et al. found an increased
rate of bowel ischemia and mortality in those patients
treated with probiotics [33]. However, a meta-analysis of
four RCTs that included severe acute pancreatitis,
including the study by Besselink et al. [38] demonstrated
that probiotics did not significantly influence mortality
either favorably or adversely. Accordingly, we should
monitor the safety of probiotics as our research efforts
move forward.
Our analysis has several limitations. First, as already
mentioned, there was heterogeneity in the inclusion cri-
teria, the populations studied, the probiotic agents used,
doses, time points when therapy was initiated, durations
of therapy, the routes of administration, and the diag-
nostic criteria used for establishing NP or VAP. These
factors were not comparable in most of the trials and
might have affected the clinical outcomes. These differ-
ences may explain the statistical heterogeneity in some
of the secondary outcomes investigated. Second, even
though we were able to pool results across all trials, the
number of patients included in this meta-analysis may
not be sufficient to exclude significant clinical benefit.
Third, most trials were done in single centers and may
have had inherent bias related to local practice habits
and the populations served. Although we extensively
searched for relevant studies using multiple databases
and multiple search items, and no language restriction
was placed on the search, a funnel plot suggested the
possibility of publication bias. Finally, the quality of the
included studies was not consistent. Some RCTs
included in our analysis had major methodological flaws
[24,28]. The quality of trials can affect the direction and
magnitude of treatment effects when performing a
meta-analysis.
Although the results have been encouraging, there is
insufficient evidence to suggest to clinicians that admin-
istration of probiotics is associated with significant clini-
cal benefit in critically ill patients. In addition, there is a
lack of head-to-head comparative trials with different
probiotics to investigate and clarify which probiotic bac-
terial strains were of most benefit to critically ill
patients. Data regarding the superiority of different
doses of probiotics and routes of administration are also
lacking. The questions that remain to be evaluated in
large-scale, randomized controlled trials of probiotics
use in NP include the optimal type of probiotic prepara-
tion, administration route, dose intensity, timing and
duration of administration, safety, patient eligibility, and
contraindications.
Conclusions
The use of probiotics was associated with statistically
significant reduction in the incidence of NP in critically
ill patients. However, there is no evidence to support or
refute claims of beneficial effects on clinically important
outcomes. Large, well-designed, randomized, multi-cen-
ter trials are needed to confirm the effects of probiotics
in diverse populations of critically ill patients.
Key messages
• Numerous studies have examined the utility of
probiotic therapy to prevent NP in critically ill
patients, but studies on the use of probiotics have
yielded mixed results.
• Probiotics administration was associated with sta-
tistically significant reduction in the incidence of NP
in critically ill patients.
• More randomized control trials are needed to defi-
nitively determine the effect of probiotics in critically
ill patients.
Additional material
Additional file 1: Forest plot showing the effect of probiotics on the
occurrence of ventilator-assisted pneumonia in critical ill patients
receiving mechanical ventilation.
Additional file 2: Forest plot showing the effect of probiotics on the
occurrence of nocosomial pneumonia in l critically ill surgical
patients.
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